Cellaegis Devices Hospital Exterior W Text Overlay Re 2800 Multi Center Hospital For Autoric Stemi Trial
ERIC-PPCI RCT
April 13, 2018
CellAegis Devices patient having ePCI Shield treatment with nurse w/ text overlay re clinical trial in 500 US hospitals
SHIELD RCT
May 15, 2018
  • Trial/Article NameField Implementation of the autoRIC Device in STEMI
  • LinkView Full Article on Pubmed
  • Location or Size of Trial1800 participants

Field Implementation of the autoRIC® Device in STEMI (FIRST)

Brief Summary

This is a "before and after" observational study of a therapeutic strategy to treat patients with confirmed ST-segment myocardial infarction (STEMI) with remote ischemic conditioning (RIC) before undergoing primary percutaneous coronary intervention (PCI). RIC is the purposeful application of brief, intermittent cycles of limb occlusion by inflation/deflation of a pneumatic cuff. The autoRIC® device is an automatic RIC delivery device (the autoRIC® Device; CellAegis Devices Inc, Toronto, ON) that has received clearance from Health Canada for this use under the direction of a health care professional. Paramedics in the Peel and Halton regional emergency services and the Emergency department (ED) staff of Brampton Civic Hospital and Mississauga Hospital will treat patients experiencing STEMI with autoRIC®, and study data will be collected from existing patient records.

The 'before' group will include up to 900 patients who were treated before autoRIC® implementation in the services and hospitals. These patients would have had a STEMI and undergone PCI, but did not receive the autoRIC® device. The 'after' group will include up to 900 eligible patients who have had RIC treatment with the autoRIC® device at the two participating sites following implementation in the services and hospitals.

The primary analyses will compare the short-term and long-term outcomes of eligible patients who have received completed primary PCI for STEMI in the time period before the implementation and following the implementation of this RIC strategy. In addition, a health economic analysis will be conducted to determine the cost-effectiveness of the therapeutic strategy to treat STEMI patients with RIC prior to PCI.

Get autoRIC®